Jiangsu Hengrui Pharmaceuticals (JHPCY) Dividend

Mixed. Jiangsu Hengrui Pharmaceuticals Co.,Ltd (JHPCY) pays a annual dividend yielding 0.48% ($0.06/yr), with 0 years of growth. The picture is mixed — the dividend pays, but safety or growth signals are weaker than ideal.

Based on a blend of discounted cash flow, a dividend-discount model and an earnings-multiple estimate, JHPCY's fair value is about $5.90 versus a $12.25 share price — so it looks overvalued (-52% vs. fair value).

Our blended fair-value estimate for JHPCY is about $5.90 per share, about 52% below the current $12.25 price — combining a discounted cash flow, a dividend-discount model and an earnings multiple.

We don't issue formal ratings, but on the data JHPCY screens as "mixed" and overvalued. Jiangsu Hengrui Pharmaceuticals Co.,Ltd (JHPCY) pays a annual dividend yielding 0.48% ($0.06/yr), with 0 years of growth. The picture is mixed — the dividend pays, but safety or growth signals are weaker than ideal. This is research for your own analysis, not investment advice.

Yes. Jiangsu Hengrui Pharmaceuticals Co.,Ltd pays a annual dividend of about $0.06 per share annually, a forward yield of roughly 0.48%.

At $0.06 per share a year, 100 shares of JHPCY pay $6.00 a year in dividends before tax, about $6.00 each year. Buying them costs about $1,225 at the Nov 5, 2026 price.

As of Nov 5, 2026, JHPCY's forward dividend yield is 0.48%, based on a $0.06 annual dividend and a $12.25 share price.

As of Nov 5, 2026, JHPCY pays $0.06 per share per year, distributed on a annual basis.

As of Nov 5, 2026, JHPCY's payout ratio is 15% of trailing 12-month earnings — a comfortable level that leaves room to keep raising the dividend.

JHPCY does not currently have a long dividend-growth streak on record.

As of Nov 5, 2026, JHPCY's next ex-dividend date hasn't been announced. The most recent was Apr 30, 2026, for $0.0582 per share.